• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    4/3/24 8:09:46 AM ET
    $ABIO
    $ACOR
    $AIH
    $ENVB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABIO alert in real time by email

    Gainers

    • ARCA biopharma (NASDAQ:ABIO) stock moved upwards by 124.6% to $3.84 during Wednesday's pre-market session. The market value of their outstanding shares is at $55.6 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares increased by 99.2% to $0.2. The market value of their outstanding shares is at $7.8 million.
    • Aesthetic Medical Intl (NASDAQ:AIH) stock rose 53.03% to $0.52. The market value of their outstanding shares is at $24.7 million.
    • OneMedNet (NASDAQ:ONMD) shares increased by 39.18% to $1.1. The company's market cap stands at $35.4 million.
    • Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 36.39% to $7.72. The company's market cap stands at $6.8 million. The company's, Q4 earnings came out 4 days ago.
    • Vanda Pharma (NASDAQ:VNDA) shares moved upwards by 34.01% to $5.24. The market value of their outstanding shares is at $301.4 million.

    Losers

    • SINTX Techs (NASDAQ:SINT) stock declined by 21.0% to $0.03 during Wednesday's pre-market session. The company's market cap stands at $1.6 million.
    • Tenon Medical (NASDAQ:TNON) stock fell 16.42% to $0.8. The market value of their outstanding shares is at $2.0 million.
    • Acorda Therapeutics (NASDAQ:ACOR) shares decreased by 11.61% to $2.21. The company's market cap stands at $2.7 million. As per the news, the Q4 earnings report came out 2 days ago.
    • Enveric Biosciences (NASDAQ:ENVB) stock fell 11.41% to $1.01. The market value of their outstanding shares is at $7.3 million.
    • Orgenesis (NASDAQ:ORGS) stock decreased by 9.47% to $0.35. The company's market cap stands at $11.9 million.
    • Mesoblast (NASDAQ:MESO) shares decreased by 7.9% to $6.07. The company's market cap stands at $615.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABIO
    $ACOR
    $AIH
    $ENVB

    CompanyDatePrice TargetRatingAnalyst
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    Mesoblast Limited
    $MESO
    12/23/2024Buy → Hold
    Jefferies
    Vanda Pharmaceuticals Inc.
    $VNDA
    10/31/2024$18.00Buy
    H.C. Wainwright
    Mesoblast Limited
    $MESO
    9/24/2024$12.00Hold → Buy
    Maxim Group
    Mesoblast Limited
    $MESO
    8/29/2024Hold → Buy
    Jefferies
    More analyst ratings

    $ABIO
    $ACOR
    $AIH
    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABIO
    $ACOR
    $AIH
    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Krause Philip R.

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/18/26 5:44:56 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Mesoblast Limited

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/18/26 9:41:13 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Mesoblast Limited

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/18/26 9:39:43 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABIO
    $ACOR
    $AIH
    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mesoblast upgraded by Jefferies

    Jefferies upgraded Mesoblast from Hold to Buy

    11/25/25 8:34:05 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $ACOR
    $AIH
    $ENVB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $ACOR
    $AIH
    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

    Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform SALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramic biomaterials and silicon nitride medical device innovation, today announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market. The procedure represents SINTX's entry int

    3/19/26 7:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

    MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence. What This Collaboration Means for the Pharma Market Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training. Navidence's platform enables precise definition of health data needs via Computable Operationa

    3/18/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Enveric Biosciences Announces Registration of Five Trademarks

    Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company's trademarks, including its house marks, Enveric and Enveric Biosciences. "The registration of a Company's house marks, such as our marks Enveric and Enveric Biosciences, is an important intellectual property milestone supporting our branding strategies for our future products. We thank the Canadian Intellectual Property

    3/18/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $ACOR
    $AIH
    $ENVB
    SEC Filings

    View All

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    3/18/26 6:53:53 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form D filed by Tenon Medical Inc.

    D - Tenon Medical, Inc. (0001560293) (Filer)

    3/17/26 9:25:50 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Orgenesis Inc. filed SEC Form 8-K: Leadership Update

    8-K - Orgenesis Inc. (0001460602) (Filer)

    3/13/26 3:48:44 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $ACOR
    $AIH
    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    $ABIO
    $ACOR
    $AIH
    $ENVB
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international

    2/4/26 6:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Solana Company Reports Third Quarter 2025 Financial Results

    NEWTOWN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter ended September 30, 2025. Third Quarter and Recent Business Updates Closed partnership with Pantera Capital and Summer Capital of over $500 Million in funding in cash and stablecoins to launch SOL treasury strategyIssued cash-exercise warrants, allowing for a potential aggregate $750M additional capital raise for the CompanyLaunched ATM program, giving the company flexibility to raise addi

    11/18/25 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ABIO
    $ACOR
    $AIH
    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:51:18 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:50:26 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care